All In Biotech

Drug Trial Radar · NCT06433609

Study of ADCs Combined With Adebrelimab in HER2-negative Advanced Breast Cancer

A Phase II Study of Antibody-Drug Conjugates (ADCs) Combined With Adebrelimab in HER2-negative Advanced Breast Cancer

Last checked: Nov 19, 2026Latest source record: Jul 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

113

Planned (sponsor's estimate)

Start

Aug 5, 2024

Primary completion

Mar 2027

Study completion Nov 2027

Sponsor

Lead sponsor
Beijing GoBroad HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
May 30, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Our study is aimed to evaluate the efficacy and safety of novel ADCs named SHR-A1811, SHR-A1921 and SHR-A2102 combined with adebrelimab in HER2-negative advanced breast cancer.

Conditions

  • Advanced Breast Cancer

Interventions

  • SHR-A1811Drug

    Via intravenous infusion

  • SHR-A1921Drug

    Via intravenous infusion

  • AdebrelimabDrug

    Via intravenous infusion

  • SHR-A2102Drug

    Via intravenous infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. ORR (objective response rate) by investigatorTime frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 3.5 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Beijing GoBroad Hospital

    Beijing, Beijing Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.